Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lineage Cell Therapeutics Inc LCTX

Healthcare Biotechnology
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and... see more

Recent & Breaking News (NYSEAM:LCTX)

Lineage to Present at Baird 2023 Global Healthcare Conference and H.C. Wainwright & Co. 25th Annual Global Investment Conference

Business Wire August 29, 2023

Lineage Cell Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Business Wire August 10, 2023

Lineage Cell Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023

Business Wire August 3, 2023

Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer

Business Wire July 24, 2023

Lineage Cell Therapeutics Expected to Be Added to Russell 3000® Index

Business Wire May 22, 2023

Lineage Cell Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Business Wire May 11, 2023

Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)

Business Wire May 9, 2023

Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023

Business Wire May 4, 2023

RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration

Business Wire April 26, 2023

Lineage to Present at 2023 AAPS National Biotechnology Conference

Business Wire April 18, 2023

Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium

Business Wire March 30, 2023

RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit

Business Wire March 20, 2023

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Business Wire March 9, 2023

RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D.

Business Wire March 6, 2023

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023

Business Wire March 2, 2023

Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications

Business Wire February 22, 2023

Lineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss

Business Wire February 8, 2023

Lineage to Present at BTIG Ophthalmology Day and the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference

Business Wire November 29, 2022

Lineage Announces Launch of Phase 2a Study by Genentech of RG6501 (OpRegen®) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Business Wire November 28, 2022

Lineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

Business Wire November 10, 2022